NERV vs NMRA
NERV: Minerva Neurosciences is a clinical-stage biopharmaceutical company developing novel treatments for central nervous system disorders, primarily focusing on schizophrenia. NMRA: Neumora Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for psychiatric and neurodegenerative brain disorders.
Side-by-side fundamentals
| Metric | NERV | NMRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.43 | $1.54 | |
| Market cap as of 2026-07-23 | $209M | $298M | |
| P/E as of 2026-07-23 | 144.94 | n/a | |
| Net margin as of 2026-07-23 | +4.7% | n/a | |
| Operating margin as of 2026-07-23 | +4.5% | n/a | |
| ROE as of 2026-07-23 | -169.6% | -181.7% | NERV higher |
| ROA as of 2026-07-23 | -662.8% | -119.2% | NMRA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.75 | NERV lower |
| Beta as of 2026-07-23 | -0.04 | 2.85 | |
| 1-year return as of 2026-07-22 close | +123.7% | -17.6% | NERV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.